|
1
|
Rubin SC, Randall TC, Armstrong KA, Chi DS
and Hoskins WJ: Ten-year follow-up of ovarian cancer patients after
second-look laparotomy with negative findings. Obstet Gynecol.
93:21–24. 1999.PubMed/NCBI
|
|
2
|
Armstrong DK: Relapsed ovarian cancer:
Challenges and management strategies for a chronic disease.
Oncologist. 7(Suppl 5): 20–28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
National Institute for Health and Care
Excellence. Guidance on the use of paclitaxel in the treatment of
ovarian cancer. http://www.nice.org.uk/guidance/ta55.
Accessed January 22, 2003
|
|
4
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Piccart MJ, Bertelsen K, James K, Cassidy
J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et
al: Randomized intergroup trial of cisplatin-paclitaxel versus
cisplatin-cyclophosphamide in women with advanced epithelial
ovarian cancer: Three-year results. J Natl Cancer Inst. 92:699–708.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsuruo T, Naito M, Tomida A, Fujita N,
Mashima T, Sakamoto H and Haga N: Molecular targeting therapy of
cancer: Drug resistance, apoptosis and survival signal. Cancer Sci.
94:15–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: From genomics to mechanism.
Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ling V: Multidrug resistance: Molecular
mechanisms and clinical relevance. Cancer Chemother Pharmacol.
40(Suppl): S3–S8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dalton WS, Crowley JJ, Salmon SS, Grogan
TM, Laufman LR, Weiss GR and Bonnet JD: A phase III randomized
study of oral verapamil as a chemosensitizer to reverse drug
resistance in patients with refractory myeloma. A Southwest
Oncology Group study. Cancer. 75:815–820. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sonneveld P, Suciu S, Weijermans P, Beksac
M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H,
Gerhartz H, et al; European Organization for Research and Treatment
of Cancer (EORTC); Leukaemia Cooperative Group (LCG); Dutch
Haemato-Oncology Cooperative Study Group (HOVON). Cyclosporin A
combined with vincristine, doxorubicin and dexamethasone (VAD)
compared with VAD alone in patients with advanced refractory
multiple myeloma: An EORTC-HOVON randomized phase III study
(06914). Br J Haematol. 115:895–902. 2001. View Article : Google Scholar
|
|
11
|
Leonard GD, Fojo T and Bates SE: The role
of ABC transporters in clinical practice. Oncologist. 8:411–424.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kliewer SA, Moore JT, Wade L, Staudinger
JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM,
Zetterström RH, et al: An orphan nuclear receptor activated by
pregnanes defines a novel steroid signaling pathway. Cell.
92:73–82. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lehmann JM, McKee DD, Watson MA, Willson
TM, Moore JT and Kliewer SA: The human orphan nuclear receptor PXR
is activated by compounds that regulate CYP3A4 gene expression and
cause drug interactions. J Clin Invest. 102:1016–1023. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bertilsson G, Heidrich J, Svensson K,
Asman M, Jendeberg L, Sydow-Bäckman M, Ohlsson R, Postlind H,
Blomquist P and Berkenstam A: Identification of a human nuclear
receptor defines a new signaling pathway for CYP3A induction. Proc
Natl Acad Sci USA. 95:12208–12213. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, LeCulyse E, Liu L, Hu M, Matoney
L, Zhu W and Yan B: Rat pregnane X receptor: Molecular cloning,
tissue distribution, and xenobiotic regulation. Arch Biochem
Biophys. 368:14–22. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blumberg B, Sabbagh W Jr, Juguilon H,
Bolado J Jr, van Meter CM, Ong ES and Evans RM: SXR, a novel
steroid and xenobiotic-sensing nuclear receptor. Genes Dev.
12:3195–3205. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pascussi JM, Jounaidi Y, Drocourt L,
Domergue J, Balabaud C, Maurel P and Vilarem MJ: Evidence for the
presence of a functional pregnane X receptor response element in
the CYP3A7 promoter gene. Biochem Biophys Res Commun. 260:377–381.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schuetz EG, Brimer C and Schuetz JD:
Environmental xenobiotics and the antihormones cyproterone acetate
and spironolactone use the nuclear hormone pregnenolone X receptor
to activate the CYP3A23 hormone response element. Mol Pharmacol.
54:1113–1117. 1998.PubMed/NCBI
|
|
19
|
de Wildt SN, Kearns GL, Leeder JS and van
den Anker JN: Cytochrome P450 3A: Ontogeny and drug disposition.
Clin Pharmacokinet. 37:485–505. 1999. View Article : Google Scholar
|
|
20
|
Ketter TA, Flockhart DA, Post RM, Denicoff
K, Pazzaglia PJ, Marangell LB, George MS and Callahan AM: The
emerging role of cytochrome P450 3A in psychopharmacology. J Clin
Psychopharmacol. 15:387–398. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Synold TW, Dussault I and Forman BM: The
orphan nuclear receptor SXR coordinately regulates drug metabolism
and efflux. Nat Med. 7:584–590. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Geick A, Eichelbaum M and Burk O: Nuclear
receptor response elements mediate induction of intestinal MDR1 by
rifampin. J Biol Chem. 276:14581–14587. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kliewer SA, Goodwin B and Willson TM: The
nuclear pregnane X receptor: A key regulator of xenobiotic
metabolism. Endocr Rev. 23:687–702. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hartley DP, Dai X, Yabut J, Chu X, Cheng
O, Zhang T, He YD, Roberts C, Ulrich R, Evers R, et al:
Identification of potential pharmacological and toxicological
targets differentiating structural analogs by a combination of
transcriptional profiling and promoter analysis in LS-180 and
Caco-2 adenocarcinoma cell lines. Pharmacogenet Genomics.
16:579–599. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guzelian J, Barwick JL, Hunter L, Phang
TL, Quattrochi LC and Guzelian PS: Identification of genes
controlled by the pregnane X receptor by microarray analysis of
mRNAs from pregnenolone 16alpha-carbonitrile-treated rats. Toxicol
Sci. 94:379–387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masuyama H, Nakatsukasa H, Takamoto N and
Hiramatsu Y: Down-regulation of pregnane X receptor contributes to
cell growth inhibition and apoptosis by anticancer agents in
endometrial cancer cells. Mol Pharmacol. 72:1045–1053. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gupta D, Venkatesh M, Wang H, Kim S, Sinz
M, Goldberg GL, Whitney K, Longley C and Mani S: Expanding the
roles for pregnane X receptor in cancer: Proliferation and drug
resistance in ovarian cancer. Clin Cancer Res. 14:5332–5340. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yue X, Akahira J, Utsunomiya H, Miki Y,
Takahashi N, Niikura H, Ito K, Sasano H, Okamura K and Yaegashi N:
Steroid and xenobiotic receptor (SXR) as a possible prognostic
marker in epithelial ovarian cancer. Pathol Int. 60:400–406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Masuyama H, Suwaki N, Tateishi Y,
Nakatsukasa H, Segawa T and Hiramatsu Y: The pregnane X receptor
regulates gene expression in a ligand- and promoter-selective
fashion. Mol Endocrinol. 19:1170–1180. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Masuyama H, Nobumoto E, Zhang G
and Hiramatsu Y: The inhibition of constitutive androstane
receptor-mediated pathway enhances the effects of anticancer agents
in ovarian cancer cells. Biochem Pharmacol. 90:356–366. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie W and Evans RM: Orphan nuclear
receptors: The exotics of xenobiotics. J Biol Chem.
276:37739–37742. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qatanani M and Moore DD: CAR, the
continuously advancing receptor, in drug metabolism and disease.
Curr Drug Metab. 6:329–339. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Petru E, Sevin BU, Perras J, Boike G,
Ramos R, Nguyen H and Averette HE: Comparative chemosensitivity
profiles in four human ovarian carcinoma cell lines measuring ATP
bioluminescence. Gynecol Oncol. 38:155–160. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smith JA, Ngo H, Martin MC and Wolf JK: An
evaluation of cytotoxicity of the taxane and platinum agents
combination treatment in a panel of human ovarian carcinoma cell
lines. Gynecol Oncol. 98:141–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Duan Z, Brakora KA and Seiden MV:
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small
interfering RNA and reversal of paclitaxel resistance in human
ovarian cancer cells. Mol Cancer Ther. 3:833–838. 2004.PubMed/NCBI
|
|
36
|
Masuyama H, Hiramatsu Y, Kunitomi M, Kudo
T and MacDonald PN: Endocrine disrupting chemicals, phthalic acid
and nonylphenol, activate Pregnane X receptor-mediated
transcription. Mol Endocrinol. 14:421–428. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Masuyama H, Hiramatsu Y, Mizutani Y,
Inoshita H and Kudo T: The expression of pregnane X receptor and
its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell
Endocrinol. 172:47–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang H, Huang H, Li H, Teotico DG, Sinz M,
Baker SD, Staudinger J, Kalpana G, Redinbo MR and Mani S: Activated
pregnenolone X-receptor is a target for ketoconazole and its
analogs. Clin Cancer Res. 13:2488–2495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang H, Wang H, Sinz M, Zoeckler M,
Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV and Mani
S: Inhibition of drug metabolism by blocking the activation of
nuclear receptors by ketoconazole. Oncogene. 26:258–268. 2007.
View Article : Google Scholar
|
|
40
|
Chen Y, Tang Y, Guo C, Wang J, Boral D and
Nie D: Nuclear receptors in the multidrug resistance through the
regulation of drug-metabolizing enzymes and drug transporters.
Biochem Pharmacol. 83:1112–1126. 2012. View Article : Google Scholar : PubMed/NCBI
|
